Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 235

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 235
---
) |     |   | December 2021 Notes Derivative |   |     |   | August 2022 Notes Derivative |   |     |   | 2022 Convertible  Notes Derivative |   |
|:------------------------------------------------------------------------|:----|:--|-------------------------------:|:--|:----|:--|-----------------------------:|:--|:----|:--|-----------------------------------:|:--|
| Balance - December 31, 2021                                             |     | $ |                        367,000 |   |     |   |                            — |   |     |   |                                  — |   |
| Addition of new derivative                                              |     |   |                              — |   |     |   |                       76,000 |   |     |   |                            221,000 |   |
| Loss (gain) on change in fair value                                     |     |   |                       (205,000 | ) |     |   |                       44,000 |   |     |   |                            350,000 |   |
| Settlements                                                             |     |   |                       (162,000 | ) |     |   |                     (120,000 | ) |     |   |                           (571,000 | ) |
| Balance - December 31, 2022                                             |     |   |                              — |   |     |   |                            — |   |     |   |                                  — |   |
| Addition of new derivatives                                             |     |   |                              — |   |     |   |                            — |   |     |   |                                  — |   |
| Gain on change in fair value                                            |     |   |                              — |   |     |   |                            — |   |     |   |                                  — |   |
| Balance - December 31, 2023                                             |     |   |                              — |   |     | $ |                            — |   |     | $ |                                  — |   |

Note 9 – Related Party Transactions

Related Party Transactions

On September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (“TCG GreenChem”), the U.S. subsidiary of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd